IIB 
115TH CONGRESS 
2D SESSION 
H. R. 5590 
IN THE SENATE OF THE UNITED STATES 
JUNE 20, 2018 
Received; read twice and referred to the Committee on Finance 
AN ACT 
To require the Secretary of Health and Human Services 
to provide for an action plan on recommendations for 
changes under Medicare and Medicaid to prevent opioids 
addictions and enhance access to medication-assisted 
treatment, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
00:35 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5590.RFS
H5590
lotter on DSKBCFDHB2PROD with BILLS
HR 5590 RFS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Opioid Addiction Ac-
tion Plan Act’’. 
SEC. 
2. 
ACTION 
PLAN 
ON 
RECOMMENDATIONS 
FOR 
CHANGES UNDER MEDICARE AND MEDICAID 
TO PREVENT OPIOIDS ADDICTIONS AND EN-
HANCE ACCESS TO MEDICATION-ASSISTED 
TREATMENT. 
(a) IN GENERAL.—Not later than January 1, 2019, 
the Secretary of Health and Human Services (in this sec-
tion referred to as the ‘‘Secretary’’), in collaboration with 
the Pain Management Best Practices Inter-Agency Task 
Force convened under section 101(b) of the Comprehen-
sive Addiction and Recovery Act of 2016 (Public Law 
114–198), shall develop an action plan that provides rec-
ommendations described in subsection (b). 
(b) ACTION PLAN COMPONENTS.—Recommendations 
described in this subsection are, based on an examination 
by the Secretary of potential obstacles to an effective re-
sponse to the opioid crisis, recommendations, as deter-
mined appropriate by the Secretary, on the following: 
(1) Recommendations on changes to the Medi-
care program under title XVIII of the Social Secu-
rity Act and the Medicaid program under title XIX 
of such Act that would enhance coverage and pay-
ment under such programs of all medication-assisted 
VerDate Sep 11 2014 
00:35 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5590.RFS
H5590
lotter on DSKBCFDHB2PROD with BILLS
HR 5590 RFS
treatment approved by the Food and Drug Adminis-
tration for the treatment of opioid addiction and 
other therapies that manage chronic and acute pain 
and treat and minimize risk of opioid addiction, in-
cluding recommendations on changes to the Medi-
care prospective payment system for hospital inpa-
tient department services under section 1886(d) of 
such Act (42 U.S.C. 1395ww(d)) and the Medicare 
prospective payment system for hospital outpatient 
department services under section 1833(t) of such 
Act (42 U.S.C. 1395l(t)) that would allow for sepa-
rate payment for such therapies, if medically appro-
priate and if necessary to encourage development 
and adoption of such therapies. 
(2) Recommendations for payment and service 
delivery models to be tested by the Center for Medi-
care and Medicaid Innovation and other federally 
authorized demonstration projects, including value- 
based models, that may encourage the use of appro-
priate medication-assisted treatment approved by the 
Food and Drug Administration for the treatment of 
opioid addiction and other therapies that manage 
chronic and acute pain and treat and minimize risk 
of opioid addiction. 
VerDate Sep 11 2014 
00:35 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5590.RFS
H5590
lotter on DSKBCFDHB2PROD with BILLS
HR 5590 RFS
(3) Recommendations for data collection that 
could facilitate research and policy making regarding 
prevention of opioid addiction and coverage and pay-
ment under the Medicare and Medicaid programs of 
appropriate opioid addiction treatments. 
(4) Recommendations for policies under the 
Medicare program and under the Medicaid program 
that can expand access for rural, or medically under-
served communities to the full range of medication- 
assisted treatment approved by the Food and Drug 
Administration for the treatment of opioid addiction 
and other therapies that manage chronic and acute 
pain and treatment and minimize risk of opioid ad-
diction. 
(5) Recommendations on changes to the Medi-
care program and the Medicaid program to address 
coverage or payment barriers to patient access to 
medical devices that are non-opioid based treatments 
approved by the Food and Drug Administration for 
the management of acute pain and chronic pain, for 
monitoring substance use withdrawal and preventing 
overdoses of controlled substances, and for treating 
substance use disorder. 
(c) STAKEHOLDER MEETINGS.— 
VerDate Sep 11 2014 
00:35 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5590.RFS
H5590
lotter on DSKBCFDHB2PROD with BILLS
HR 5590 RFS
(1) IN GENERAL.—Beginning not later than 3 
months after the date of the enactment of this Act, 
the Secretary shall convene a public stakeholder 
meeting to solicit public comment on the components 
of the action plan recommendations described in 
subsection (b). 
(2) PARTICIPANTS.—Participants of meetings 
described in paragraph (1) shall include representa-
tives from the Food and Drug Administration and 
National Institutes of Health, biopharmaceutical in-
dustry members, medical researchers, health care 
providers, the medical device industry, the Medicare 
program, the Medicaid program, and patient advo-
cates. 
(d) REQUEST FOR INFORMATION.—Not later than 3 
months after the date of the enactment of this section, 
the Secretary shall issue a request for information seeking 
public feedback regarding ways in which the Centers for 
Medicare & Medicaid Services can help address the opioid 
crisis through the development of and application of the 
action plan. 
(e) REPORT TO CONGRESS.—Not later than June 1, 
2019, the Secretary shall submit to Congress, and make 
public, a report that includes— 
VerDate Sep 11 2014 
00:35 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5590.RFS
H5590
lotter on DSKBCFDHB2PROD with BILLS
HR 5590 RFS
(1) a summary of recommendations that have 
emerged under the action plan; 
(2) the Secretary’s planned next steps with re-
spect to the action plan; and 
(3) an evaluation of price trends for drugs used 
to reverse opioid overdoses (such as naloxone), in-
cluding recommendations on ways to lower such 
prices for consumers. 
(f) DEFINITION OF MEDICATION-ASSISTED TREAT-
MENT.—In this section, the term ‘‘medication-assisted 
treatment’’ includes opioid treatment programs, behav-
ioral therapy, and medications to treat substance abuse 
disorder. 
Passed the House of Representatives June 19, 2018. 
Attest: 
KAREN L. HAAS, 
Clerk. 
VerDate Sep 11 2014 
00:35 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H5590.RFS
H5590
lotter on DSKBCFDHB2PROD with BILLS